Tomas Pokrivcak, MD, PhD· @pokrivcak · X·· 2 天前评分70
正文 · 原文
Phase II data in locally advanced penile SCC at #ESMO26
Neoadjuvant toripalimab + TIP (n=25): • ORR 84% | pCR 48% • 1y EFS 72% | OS 88% • G3–4 AEs: 84% • HPV+ vs HPV−: pCR 67% vs 33% (NS)
Encouraging efficacy, substantial toxicity. Validation needed.
#PenileCancer
23 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial
https://esmocongress.esmo.org来源：Tomas Pokrivcak, MD, PhD · x.com